Back to People

Dr. Robert Buchanan has over 20 years of experience in senior company management roles in the United States and Europe. He is currently an Entrepreneur-In-Residence at the University of Miami (UM) and a board member of UM’s Wallace H. Coulter Center (WHCC) which is focused on commercializing innovative biomedical and engineering discoveries. He is also co-founder, and Chief Executive Officer of UM’s first cell and gene therapy spin-out called Ambulero which is focused on bringing new treatments to vascular disease patients. Robert is also a co-founder and board member of RORA Biologics: a spin-out of Case Western Reserve University and Emory University that is using a newly discovered subset of stem-like T-cells to build new oncology and HIV drugs. Other past executive roles include serving as General Counsel for Avexxin AS (now Coegin Pharma AB, COEGIN: Nordic GM), co-founder and Chief Executive Officer of Regenesance BV (now Complement Pharma BV), co-founder and early advisor to Idogen AB (IDOGEN: ST), and Associate General Counsel at Biogen (NASDAQ:BIIB) where responsibilities included oversight of the company’s early stage hemophilia and gene therapy patent portfolios.

Earlier in his career, Robert was a partner and co-chair of the Life Sciences Practice Group of Edwards Angell Palmer & Dodge (now Locke Lord). He received a BS from the University of Massachusetts, Amherst (Biochemistry, cum laude), a PhD from the University of California, Los Angeles (Biochemistry), and a JD in law from Suffolk University, Boston. He is also a past Biology Fellow with the California Institute of Technology where his research was supported by a McKnight Endowment Fund For Neuroscience Award, French Foundation For Alzheimer Research Fellowship; and a United States National Research Award Postdoctoral Fellowship. Robert is a registered patent attorney with the United States Patent & Trademark Office and is licensed to practice law before state courts in Massachusetts and the US District Court of Massachusetts.